Tate & Lyle plans to pass higher costs into customer contracts renewed for 2027, the food ingredients supplier said in its half-year results on 5 November. The warning comes as sales return to growth but profitability falls.

The company links the increased cost pressure to the prolonged Middle East conflict. It also plans to limit the impact through procurement and tighter operating discipline.

For food and drink manufacturers, the immediate issue is the next round of ingredient agreements. Tate & Lyle has not announced a single percentage increase across its portfolio. Nor does the statement establish how much, if anything, supermarket shelf prices will rise.

The group supplies sweeteners, starches, fibres and stabilising ingredients. These help manufacturers control sweetness, texture, nutrition and product stability across drinks, dairy, bakery, sauces and other grocery categories.

That puts the announcement upstream of many UK supermarket suppliers. The commercial effect will depend on the ingredients used, contract terms and the proportion of each finished product’s cost represented by those inputs.

Revenue reached £1.039 billion in the six months to 30 September 2026. Growth was 1% at constant currency. Adjusted earnings before interest, tax, depreciation and amortisation fell 8% to £197 million.

Statutory profit before tax dropped 37% to £46 million. The adjusted measure fell 18% to £102 million. Keeping those measures separate matters: the figures describe different views of profitability.

The sales recovery also needs qualification. Tate & Lyle reported 3% growth in volume/mix, partly offset by a 2% price decline. Volume/mix measures the revenue effect of both quantities sold and the mix of ingredients. It is not simply a measure of tonnes shipped.

Pricing actions taken during renewals for the 2026 calendar year helped support that recovery. The proposed cost pass-through for 2027 therefore follows a period in which lower prices supported customer demand.

Performance varied across regions. Americas revenue increased 1% at constant currency to £521 million. Asia Pacific grew 7% to £210 million. Europe, the Middle East and Africa declined 4% to £308 million, with flat volume/mix and lower pricing.

Those differences argue against treating the announcement as a uniform global price change. Buyers will need the terms relevant to their own market and ingredient specification before assessing the effect on a supply agreement.

Reformulation is another part of that calculation. For private-label bakery manufacturers, changing an ingredient can affect texture, processing and the finished product’s specification. A cheaper input is not automatically a lower-cost recipe once testing and production requirements are included.

Across the wider sector, food ingredient demand remains an important measure of manufacturers’ activity. Supplier revenue, however, also reflects pricing and product mix, making the underlying drivers more useful than a headline sales figure alone.

Tate & Lyle maintained its outlook for the year ending 31 March 2027. It expects modest revenue growth and broadly flat adjusted EBITDA before an approximately US$20 million impact from rescheduling the consolidation of bio-gums capacity.

The planned acquisition by Ingredion remains subject to regulatory processes. Tate & Lyle continues to expect completion in the second half of calendar 2027.

The next commercial test is the renewal of 2027 customer agreements: whether cost recovery can protect margins while preserving the volume-led sales recovery.

Editor’s Note: Based on Tate & Lyle’s 5 November 2026 results statement. Buyer implications are GTN analysis; no specific retail price increase has been announced.